At a glance
| Question | CJC-1295 | Sermorelin |
|---|---|---|
| Core biology | Long-acting GHRH analogue designed for prolonged exposure. | GHRH(1-29)-NH2, the active N-terminal GHRH fragment. |
| Human evidence | Early randomized pharmacology studies show sustained GH and IGF-1 effects. | Older controlled human studies clearly demonstrate GH stimulation and characterize dose-response. |
| What evidence proves | Biological activity on the GH/IGF-1 axis. | Ability to stimulate endogenous GH release. |
| What it does not prove | Broad anti-ageing, recovery, muscle or longevity benefits. | Broad anti-ageing, physique or longevity benefits. |
| Regulatory framing | Investigational/unapproved for popular consumer uses. | Historical clinical/endocrine use does not equal a current FDA-approved anti-ageing treatment. |
What matters most
The useful comparison is not which peptide is ‘better’; it is how different molecular designs alter GH-axis pharmacology and how limited that tells us about long-term clinical outcomes in healthy people.